CompletedNot Applicable

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Pakistan195 participantsStarted 2023-12-01

Plain-language summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Who can participate

Age range30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: patients who were already on statins Exclusion Criteria: hereditary diseases including familial hypercholesterolemia and kidney diseases

What they're measuring

impact of rosuvstatin over LDL, CPK and AST levels

Timeframe: 12 weeks

impact of rosuvstatin over LDL, CPK and AST levels

Timeframe: 12 weeks

impact of rosuvstatin over LDL, CPK and AST levels

Timeframe: 12 weeks

Trial details

NCT IDNCT06910098

SponsorCentral Park Medical College

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More LDL - Low Density Lipoprotein Receptor Disorder trials